June 1, 2020: We have been entrusted with the development of an allogeneic bone marrow-derived mesenchymal stromal cell therapeutic agent (Stempeucel®) owned by Stempeutics Research India for patients with Buerger’s disease in Japan.

Novumcella Inc. cooperated with Stempeutics Research India on May 28, 2020 to commission the development of Stempeucel® products for the Japanese market for treating severe extremity ischemia due to Burger’s disease.
The details are as follows.https://novumcella.com/en/wp-content/uploads/83f327180f63eeb37aea8ec49415ca44.pdf